Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
The Michael Brigham Fund for Kidney Cancer Research (MBF) was established in 2011 by a dear Dartmouth friend, Al Gordon, when Michael Brigham, a long-time resident of Acton, MA lost his battle with kidney cancer. For twenty-five years Mike was an integral part of the Acton-Boxborough sports community. He coached little league, was instrumental in the formation of the town’s Community Education Basketball Program and was a varsity basketball coach. He was a mentor, coach and friend to a generation of young adults in the community. Mike loved family, and was a kind and loyal friend who shared his great sense of humor with everyone.
Since Mike’s passing, his friends and family have made a dedicated effort through a silent auction, bowling and golf events to support this fund for kidney cancer research at Dana-Farber Cancer Institute in Boston, MA. This year marks the 11th anniversary of the start of the MBF, but 10th anniversary of the golf event, since we could not hold an in-person event last year. Many attended the first event with heavy hearts, but all were determined to make this fund both a driving force for kidney cancer research, and a way to honor Mike’s legacy. We are planning to make this year a very special one and are hoping to be joined by lots of family and friends (hometown, Dartmouth, Touch and Acton folks) for golf, dinner, silent auction, and 50/50 raffle.
The MBF is guided by the research of Dr. Toni Choueiri, Director of the Kidney Cancer Center at Dana-Farber Cancer Institute. His research focuses on both treatment and cure. With the help of supporters such as the MBF, Dr. Choueiri and his team are spearheading groundbreaking studies and clinical trials with the potential to change the status quo of kidney cancer care.